0001127602-21-007951.txt : 20210225 0001127602-21-007951.hdr.sgml : 20210225 20210225175428 ACCESSION NUMBER: 0001127602-21-007951 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210223 FILED AS OF DATE: 20210225 DATE AS OF CHANGE: 20210225 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hoge Stephen CENTRAL INDEX KEY: 0001760669 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38753 FILM NUMBER: 21682245 MAIL ADDRESS: STREET 1: C/O MODERNA, INC. STREET 2: 200 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Moderna, Inc. CENTRAL INDEX KEY: 0001682852 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 813467528 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6177146500 MAIL ADDRESS: STREET 1: 200 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Moderna Therapeutics, Inc. DATE OF NAME CHANGE: 20160822 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2021-02-23 0001682852 Moderna, Inc. MRNA 0001760669 Hoge Stephen C/O MODERNA, INC. 200 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 1 President Common Stock 2021-02-23 4 M 0 10000 .99 A 1629597 D Common Stock 2021-02-23 4 S 0 500 136.83 D 1629097 D Common Stock 2021-02-23 4 S 0 300 137.97 D 1628797 D Common Stock 2021-02-23 4 S 0 200 139.14 D 1628597 D Common Stock 2021-02-23 4 S 0 200 140.15 D 1628397 D Common Stock 2021-02-23 4 S 0 300 141.61 D 1628097 D Common Stock 2021-02-23 4 S 0 1300 143.49 D 1626797 D Common Stock 2021-02-23 4 S 0 1564 144.58 D 1625233 D Common Stock 2021-02-23 4 S 0 1100 145.48 D 1624133 D Common Stock 2021-02-23 4 S 0 1200 146.73 D 1622933 D Common Stock 2021-02-23 4 S 0 1551 147.85 D 1621382 D Common Stock 2021-02-23 4 S 0 800 148.78 D 1620582 D Common Stock 2021-02-23 4 S 0 685 149.98 D 1619897 D Common Stock 2021-02-23 4 S 0 5300 150.62 D 1614597 D Common Stock 2021-02-24 4 S 0 5000 150.41 D 1609597 D Common Stock 4116 I By Valhalla, LLC Common Stock 151933 I By Trust Stock Option (Right to Buy) .99 2021-02-23 4 M 0 10000 0 D 2023-08-19 Common Stock 10000 597431 D The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $136.71 to $137.05. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $137.85 to $138.07. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $138.90 to $139.38. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $140.10 to $140.20. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $141.37 to $141.91. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $142.96 to $143.90. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $144.06 to $145.05. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $145.10 to $146.04. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $146.30 to $147.22. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $147.36 to $148.31. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $148.37 to $149.10. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $149.51 to $150.42. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $150.60 to $151.05. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. This option is fully vested and exercisable. /s/ Brian Sandstrom, as Attorney-in-Fact 2021-02-25